Fibromyalgia & musculoskeletal pain
Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial
Primary result · Mean change in pain intensity (NRS)Result — go to the resultBetween-group difference −0.7 points 95% CI −1.2 to −0.25Authors' conclusion
The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia.
Study context
- Population
- Patients with fibromyalgia from a specialised outpatient clinic in Denmark273 screened
- Participants
- 200 patients
- Comparison
- Cannabidiol (CBD) 50 mg vs placebo tablets
- CBDn = 100
- Placebon = 100reference
- Primary endpoint
- Change in pain intensity (numeric rating scale (NRS) pain subitem of the revised Fibromyalgia Impact Questionnaire)
- Follow-up
- Week 24
Methodological detailsdouble-blind, placebo-controlled, parallel-group, single-centre, stratified by sex, age and pain level
- Double-blind
- Placebo-controlled
- Parallel-group
- Single-centre
- Stratified by sex, age and pain level
Primary result
Mean change in pain intensity (NRS)
Between-group difference
−0.7 points
95% CI −1.2 to −0.25
P = 0.0028
Change by group
CBD
−0.4
mean · 95% CI −0.82–0.08 · points
Placebo
−1.1
mean · 95% CI −1.53–-0.63 · points
Placebovs CBD
between-group difference −0.7 points (95% CI −1.2 to −0.25); P = 0.0028
As reported in the abstract
Safety
Adverse events
- Generally mild and evenly distributed between groups
- Safety population
Original publication
Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Ann Rheum Dis. Published 22 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →